Novartis Pharm Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NOVARTIS PHARM, and when can generic versions of NOVARTIS PHARM drugs launch?
NOVARTIS PHARM has five approved drugs.
There are fourteen US patents protecting NOVARTIS PHARM drugs.
There are three hundred and fifty-one patent family members on NOVARTIS PHARM drugs in fifty-four countries and ninety-two supplementary protection certificates in seventeen countries.
Summary for Novartis Pharm
International Patents: | 351 |
US Patents: | 14 |
Tradenames: | 5 |
Ingredients: | 5 |
NDAs: | 5 |
Patent Litigation for Novartis Pharm: | See patent lawsuits for Novartis Pharm |
Drugs and US Patents for Novartis Pharm
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-003 | Jul 7, 2015 | RX | Yes | Yes | 9,517,226 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-001 | May 6, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-001 | May 6, 2020 | RX | Yes | No | 8,420,645 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-002 | May 6, 2020 | RX | Yes | Yes | 8,901,123 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-002 | Jul 7, 2015 | RX | Yes | No | 9,517,226 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Novartis Pharm
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis Pharm | AFINITOR DISPERZ | everolimus | TABLET, FOR SUSPENSION;ORAL | 203985-002 | Aug 29, 2012 | 6,004,973*PED | ⤷ Try a Trial |
Novartis Pharm | AFINITOR DISPERZ | everolimus | TABLET, FOR SUSPENSION;ORAL | 203985-001 | Aug 29, 2012 | 7,297,703*PED | ⤷ Try a Trial |
Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-003 | Mar 30, 2015 | 6,465,504 | ⤷ Try a Trial |
Novartis Pharm | AFINITOR DISPERZ | everolimus | TABLET, FOR SUSPENSION;ORAL | 203985-001 | Aug 29, 2012 | 5,665,772*PED | ⤷ Try a Trial |
Novartis Pharm | AFINITOR DISPERZ | everolimus | TABLET, FOR SUSPENSION;ORAL | 203985-002 | Aug 29, 2012 | 8,778,962*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for NOVARTIS PHARM drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets for Oral Suspension | 2 mg, 3 mg and 5 mg | ➤ Subscribe | 2016-12-30 |
➤ Subscribe | Tablets | 90 mg and 360 mg | ➤ Subscribe | 2015-10-19 |
➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2016-04-28 |
➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2006-03-02 |
➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2015-10-23 |
International Patents for Novartis Pharm Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 20090094299 | ⤷ Try a Trial |
Denmark | 2887961 | ⤷ Try a Trial |
Denmark | 1948158 | ⤷ Try a Trial |
New Zealand | 600626 | ⤷ Try a Trial |
Mexico | 2021000595 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Novartis Pharm Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3172209 | 122022000076 | Germany | ⤷ Try a Trial | PRODUCT NAME: CAPMATINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/22/1650 20220620 |
2269604 | 93320 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: EVEROLIMUS OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/09/538-001-006 - AFINITOR - EVEROLIMUS |
1467728 | 19/2016 | Austria | ⤷ Try a Trial | PRODUCT NAME: SACUBITRIL/VALSARTAN, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/15/1058 20151119 |
0914118 | C00914118/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: DEFERASIROX; REGISTRATION NUMBER/DATE: SWISSMEDIC 57466 03.11.2005 |
3342411 | LUC00148 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: EVEROLIMUS; AUTHORISATION NUMBER AND DATE: EU/1/09/538/001-008 20110830 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.